21 completed. 21 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 21 |
| Phase 2 | 12 | Completed 12 |
Follow Death: new trials by email Literature Review of Death trials Research Report on Death
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) RGX-121 - Mucopolysaccharidosis Type II (MPS II) | Phase 1 / Phase 2 | Completed | REGENXBIO Inc. | 6 | 2021-03-11 | 2025-01-28 |
| Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant CD3/CD19 neg allogeneic BMT - Primary Immunodeficiency, PID | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2017-12-01 | 2025-07-22 |
| Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury BQ-A Peptide Extract, Mesenchymal Stem Cells, Transcranial Laser Therapy - Brain Death | Phase 1 | Completed | Bioquark Inc. | 20 | 2016-07-01 | 2020-10-01 |
| Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome Eleclazine, Placebo - LQT2 Syndrome | Phase 1 | Completed | Gilead Sciences | 13 | 2015-07-20 | 2020-12-30 |
| Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome AGT-182 - Mucopolysaccharidosis II | Phase 1 | Completed | ArmaGen, Inc | 6 | 2015-04-01 | 2018-09-18 |
| The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon Wobenzym plus, PL 1 - Inflammation, Death, Sudden, Cardiac | Phase 1 | Completed | Technical University of Munich | 160 | 2013-08-01 | 2015-06-30 |
| Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning? Pralidoxime - Deaths | Phase 1 | Completed | Sheri Kashmir Institute of Medical Sciences | 100 | 2012-04-01 | 2014-01-20 |
| Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation EVLP Group - Disorder Related to Lung Transplantation, Brain Death | Phase 1 | Completed | Policlinico Hospital | 7 | 2011-01-01 | 2013-10-23 |
| An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment Idursulfase-IT, Elaprase - Hunter Syndrome | Phase 1 / Phase 2 | Completed | Takeda | 15 | 2010-08-01 | 2025-08-06 |
| To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients GC1111_0.5mg/kg, GC1111_1.0mg/kg, Elaprase_0.5mg/kg - Mucopolysaccharidosis II | Phase 1 / Phase 2 | Completed | Green Cross Corporation | 31 | 2010-05-01 | 2012-02-14 |
| A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase® Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg) - Hunter Syndrome | Phase 1 / Phase 2 | Completed | Shire | 16 | 2009-11-18 | 2021-06-28 |
| Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker Omegaven, Isotonic saline - Ventricular Tachycardia, Sudden Cardiac Death | Phase 1 / Phase 2 | Completed | Aalborg University Hospital | 8 | 2007-10-01 | 2015-04-16 |
| Automatic External Defibrillation Monitoring in Cardiac Arrest Defibrillation of pulseless VT/VF by AECD - Death, Sudden, Cardiac, Ventricular Fibrillation | Phase 1 | Completed | Foundation for Atlanta Veterans Education and Research, Inc. | 192 | 2006-10-01 | 2015-07-15 |
| Efficacy Study of the Non-Pneumatic Anti-Shock Garment (NASG) in Egypt Non-pneumatic Anti-shock Garment (NASG) - Hypovolemic Shock, Hemorrhage | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 990 | 2006-04-01 | 2013-05-14 |
| Thyroxine Replacement in Organ Donors L-thryoxine, iv thryoxine - Brain Death | Phase 1 / Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 34 | 2004-12-01 | 2011-01-05 |
| Development and Evaluation of a New Palliative Care Service for People Severely Affected With Multiple Sclerosis (MS) Palliative care service - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | King's College London | 52 | 2004-03-01 | 2009-06-11 |
| Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy recombinant human erythropoietin - Hypoxic-Ischemic Encephalopathy | Phase 1 / Phase 2 | Completed | Zhengzhou University | 167 | 2003-08-01 | 2008-12-16 |
| Systemic Hypothermia Improves Outcome of Hypoxic-Ischemic Encephalopathy hypothermia - Hypoxic-Ischemic Encephalopathy | Phase 1 / Phase 2 | Completed | Zhengzhou University | 100 | 2002-07-01 | 2009-01-06 |
| Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies PETN, Placebo control - High Risk Pregnancy | Phase 1 / Phase 2 | Completed | University of Jena | 111 | 2002-04-01 | 2011-05-27 |
| Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome multi micronutrient supplement, MN1, MN2 - Pregnancy, Birth Weight | Phase 1 | Completed | Bandim Health Project | 2100 | 2001-01-01 | 2013-11-18 |
Showing 20 of 21. Sign in to see all of them.
Death, Sudden, Cardiac (5) · Mucopolysaccharidosis II (5) · Sudden Infant Death (5) · Brain Death (3) · Asphyxia (2) · Hypoxia-Ischemia, Brain (2) · Lysosomal Storage Diseases (2) · Perinatal Death (2) · Tachycardia, Ventricular (2) · Abruptio Placentae (1) · Birth Weight (1) · Blood Coagulation Disorders (1) · Cardiovascular Diseases (1) · Death, Sudden (1)
Pathological Conditions, Signs and Symptoms (21) · Pathologic Processes (20) · Nervous System Diseases (11) · Death, Sudden (9) · Neurobehavioral Manifestations (8) · Neurologic Manifestations (8) · Cardiovascular Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Brain Diseases (5) · Carbohydrate Metabolism, Inborn Errors (5) · Central Nervous System Diseases (5) · Connective Tissue Diseases (5) · Genetic Diseases, X-Linked (5)
Oximes (1) · Palliative Care (1) · Sodium Chloride (1) · Thyroxine (1) · Wobenzym (1) · eleclazine (1) · fish oil triglycerides (1) · idursulfase (1) · pralidoxime (1)
Zhengzhou University (2) · Aalborg University Hospital (1) · ArmaGen, Inc (1) · Bandim Health Project (1) · Bioquark Inc. (1) · Foundation for Atlanta Veterans Education and Research, Inc. (1) · Gilead Sciences (1) · Green Cross Corporation (1) · King's College London (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Nursing Research (NINR) (1) · Policlinico Hospital (1) · REGENXBIO Inc. (1) · Sheri Kashmir Institute of Medical Sciences (1)
United States (8) · Canada (3) · Germany (3) · United Kingdom (3) · China (2) · India (2) · Denmark (1) · Egypt (1) · Guinea-Bissau (1) · Italy (1) · Philippines (1) · South Korea (1)
Changlian Zhu, MD, PhD (2) · A. Maziar Zafari, M.D., Ph.D (1) · Cynthia Dougherty, ARNP, PhD (1) · Franco Valenza, MD (1) · Himanshu Bansal, MD (1) · Irene J Higginson, BMBS FRCP FFPHM PhD (1) · Johannes Scherr, Dr. med. (1) · Michael D Sharpe, MD FRCPC (1) · Patrice Rioux, MD PhD (1) · Paul Szabolcs, MD (1) · Peter Aaby, Dr. Med (1) · Polly Edmonds, FRCP (1) · Showkat Gurcoo, MD (1)
PMID 16015266, PMID 16553654, PMID 17058754, PMID 18507817, PMID 18547438, PMID 18805742, PMID 19280394, PMID 19833477, PMID 20809942, PMID 20955600, PMID 21190486, PMID 21978993, PMID 23497636, PMID 23884915, PMID 24559067, PMID 24628890, PMID 26093876, PMID 29370708, PMID 35588317
R01NR004766 (1), U01AI125050 (1)